It was 1984. We were at the beginning of our future. We needed to define what our ‘corporate DNA’ was. To us, the answer was obvious and fundamental. We were going to focus on achieving superior clinical outcomes (nothing less would be acceptable). We were going to produce truly innovative products (no “me-too” products would do). And finally, we were going to form true collaborative partnerships with scientists who were recognized and honored in their individual fields. These scientists would need support for their research and people with the business skills necessary to bring the resulting products to the marketplace. The result? From that very first year, BDC began fusing business with science. In other words, this is who we are. This is the reason why we do what we do.
From the very start, everyone at BDC has understood that what we do is link innovations with tomorrow’s consumers. And the way we make that happen is by bringing new medical technologies all the way from the development process into commercialization. We connect breakthrough technologies with the right expertise. It’s a very flexible, efficient, and streamlined process. And it allows our innovative products to go from our lab. To the marketplace. To you.
By the way, if you know a fair amount about how many technology companies operate, you will immediately understand that the BDC business model is both distinctive and rare. It also gives you an added insight into how we manage to consistently build success upon success.
How is our research and development funded? BDC’s capital-efficient development model uses non-dilutive government funding to demonstrate the safety of new products and prove the feasibility of high-risk technologies. To date, we have secured more than sixty SBIR/STTR grant awards from the National Institutes of Health and other sources. BDC’s model has been successful, historically, because we are totally committed to combining rigorous and systematic processes with an accomplished staff. And we back that up with essential laboratory and manufacturing facilities. It all works together, accelerating technology transfer and commercialization.
Skill Sets, Competencies, and Know-How:
Grant Writing: 60+ funded NIH SBIR/STTR grants
Clinical Trials: 20+ clinical studies completed under Good Clinical Practices
Regulatory: IND and 510(k) filings
Manufacturing: Quality systems and current Good Manufacturing Practices
Formulation Development: from the bench to manufacturing
If you would like to view funded BDC projects on the NIH Website
Type: ‘Biomedical Development Corporation’ in the Institute Block and select multiple years.